Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Gain-of-function RAS gene mutations (HRAS, NRAS, KRAS) drive tumorigenesis.
• RAS proteins lack traditional drug-binding sites, complicating direct targeting.
• Previous strategies focused on indirect methods to inhibit RAS signaling.

Purpose of the Study:

• To review KRAS mutations and functions in human tumors.
• To analyze indirect and direct strategies for targeting the oncogenic RAS network.
• To discuss the development and clinical evaluation of KRAS-G12C inhibitors.

Main Methods:

• Literature review of RAS mutations, functions, and targeting strategies.
• Analysis of mechanistic principles for direct and indirect RAS inhibition.
• Evaluation of clinical trial data for KRAS-G12C inhibitors (sotorasib, adagrasib).

Main Results:

• KRAS-G12C variant possesses a druggable pocket, enabling covalent inhibitor design.
• Sotorasib and adagrasib show improved potency, selectivity, and bioavailability.
• These inhibitors are being evaluated in clinical trials for non-small cell lung cancer.

Conclusions:

• Direct targeting of KRAS-G12C is now feasible, revolutionizing precision oncology.
• Understanding resistance mechanisms is crucial for sustained therapeutic benefit.
• KRAS-G12C inhibitors represent a significant advancement in cancer therapy.